SOLID TUMOR MALIGNANCIES

This early-phase study tests a new drug called KQB365 in adults with advanced solid tumors that have KRAS G12S or G12C mutations and no standard treatment options. The main goals are to find a safe dose and see if KQB365 alone or combined with other drugs (cetuximab or KQB198) ca…

This early-stage trial tests a new treatment called GO306, a modified virus designed to infect and destroy cancer cells. It is for 32 adults with advanced solid tumors that have not responded to standard therapies. The study aims to find the safest dose and check for side effects…

This early-phase study tests an experimental drug called AO-252 in people with advanced solid tumors (cancers) that have spread to the brain or other parts of the body. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow thei…

This early-phase study tests a new drug called VIR-5525, alone or with an immunotherapy (pembrolizumab), in adults with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. Up to 450 participants will be enrolled acros…

This early-phase study tests TJ101, an experimental antibody-drug conjugate, in 200 adults with advanced solid tumors (lung, prostate, esophageal, and others) who have no standard options left. The main goals are to find a safe dose and check for early signs of tumor shrinkage. P…

This early-phase study tests a new oral drug, KQB168, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to immunotherapy. The main goals are to find a safe dose and see if the drug can shrink tumors. About 84 participants will take the…

This early-phase study tests a new tablet called SWA1211 in 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will be closely monito…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if CP-383 can slow or stop cancer growth and to find the safest dose. About 150 participants will take the drug daily and ha…

This early-stage study tests a new drug called SH009 in about 150 people with advanced solid tumors (like liver, lung, or breast cancer) that have not responded to standard treatments. The main goal is to see if the drug is safe and can shrink tumors. Researchers will also measur…

This early-stage trial tests a new drug called KQB548 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have a specific genetic change called KRAS G12D. The main goals are to find a safe dose and see if the drug can shrink tumors. About 78 pa…

This study tests a drug called valemetostat in people with advanced solid tumors that have certain gene changes (like SMARCB1 or ARID1A). The drug aims to reactivate protective genes to slow or stop cancer growth. About 900 adults will take the drug daily for up to 2 years, with …

This study tests if a drug called Pedmark (sodium thiosulfate) can reduce hearing loss in adults receiving cisplatin chemotherapy for cancers like testicular, head and neck, or thoracic cancer. About 25 participants will receive Pedmark alongside their standard chemo. The goal is…

This early-stage study tests a new injection called SXRN in 54 adults with advanced cancer who are losing weight and appetite. The goal is to find a safe dose and see if it helps improve appetite and weight. Participants will receive the drug alone or with standard cancer treatme…

This study is testing a new approach called xDRIVE that combines lab tests on tumor samples with artificial intelligence to suggest personalized cancer treatments. It involves 210 Florida patients with cancers that have come back or not responded to standard therapy, including ch…

This study looks at whether a sample of spinal fluid can find cancer DNA in people whose solid tumors have spread to the brain or its lining. Researchers will compare results from 60 participants with different types of brain involvement. The goal is to see if this liquid biopsy …

This study looks at how the cancer drug olutasidenib changes the way the body processes other medications. Researchers will give a mix of test drugs to 16 adults with IDH1-mutated cancers (like AML or certain brain tumors) and measure their levels in the blood before and after ol…

This study is for adults with solid tumors who are eligible for pembrolizumab or nivolumab. It compares higher doses (every 4-6 weeks) to lower doses (every 2-3 weeks) to see which causes fewer severe immune-related side effects. The goal is to find the safest dosing schedule wit…

This study is for people with advanced cancers that are no longer responding to standard treatments. Researchers will take a small sample of the tumor and grow it in the lab to test which drugs might work best. The goal is to see if this approach can help doctors choose more effe…